Core Points - Huntsman Corporation declared a cash dividend of $0.25 per share on its common stock, payable on September 30, 2025, to stockholders of record as of September 15, 2025 [1] - Huntsman Corporation reported approximately $6 billion in revenues for 2024, indicating a strong market presence in the specialty chemicals sector [2] - The company operates over 60 manufacturing, R&D, and operations facilities across approximately 25 countries, employing around 6,300 associates [2]

Core Insights - Huntsman Corporation reported a significant net loss of $158 million for Q2 2025, compared to a net income of $22 million in Q2 2024, indicating a challenging financial environment [2][10] - The company's revenues decreased to $1,458 million in Q2 2025 from $1,574 million in Q2 2024, reflecting a 7% decline [2][10] - Adjusted EBITDA fell to $74 million in Q2 2025, down from $131 million in the same period last year, highlighting operational difficulties [2][10] Financial Performance - Revenues for the first half of 2025 totaled $2,868 million, down from $3,044 million in the first half of 2024 [13] - The diluted loss per share for Q2 2025 was $0.92, compared to a diluted income per share of $0.13 in Q2 2024 [10][13] - Free cash flow from continuing operations improved to $55 million in Q2 2025, up from $5 million in Q2 2024 [7][10] Segment Analysis - The Polyurethanes segment saw a revenue decrease of 7% year-over-year, primarily due to lower average selling prices and sales volumes [4][13] - Performance Products segment revenues declined by 10%, driven by lower sales volumes despite stable average selling prices [5][13] - Advanced Materials segment revenues fell by 5%, attributed to lower average selling prices and reduced demand in coatings and aerospace markets [6][13] Cost Management and Restructuring - The company is implementing cost reduction measures, including the closure of its European Maleic Anhydride facility and a global workforce reduction of nearly 10% [3] - Restructuring efforts initiated at the end of 2024 have expanded in 2025, reflecting the need to adapt to current market conditions [3] Liquidity and Capital Resources - As of June 30, 2025, Huntsman had approximately $1.3 billion in combined cash and unused borrowing capacity [7] - Capital expenditures for Q2 2025 were $37 million, down from $50 million in Q2 2024, with expectations to spend between $180 million to $190 million for the full year [8][10] Tax and Effective Rates - The effective tax rate for Q2 2025 was reported at -5%, indicating a unique tax situation for the period [9]

Core Viewpoint - Ashland reported a significant decline in revenue and adjusted EBITDA for Q3 FY2025, falling short of analysts' expectations, with management signaling caution due to ongoing market softness and macroeconomic uncertainty [1][15][17] Financial Performance - Revenue for Q3 FY2025 was $463 million, missing consensus estimates by $13.6 million, and down 14.9% year-over-year from $544 million [2][5] - Non-GAAP EPS from continuing operations was $1.04, below the $1.20 consensus and down 30.2% from $1.49 in Q3 FY2024 [2][12] - Adjusted EBITDA was $113 million, a decrease of 18.7% from $139 million in the prior year [2][12] - Ongoing free cash flow was $108 million, down from $112 million in Q3 FY2024 [2][11] Business Overview and Strategic Focus - Ashland operates in various markets including pharmaceuticals, personal care, coatings, and industrial materials, focusing on performance-enhancing ingredients [3] - The company is engaged in portfolio optimization, emphasizing high-value specialty offerings and operational efficiency [4][17] Segment Performance - Life Sciences segment saw a 17% decline in sales, but a 4% organic increase in pharmaceutical applications [6] - Personal Care revenue declined 16%, with a 27.9% Adjusted EBITDA margin despite lower sales [7] - Specialty Additives experienced a 13% sales drop, with Adjusted EBITDA falling 32% to $26 million [8][9] - Intermediates segment reported a sales decline, with Adjusted EBITDA down 22% [10] Cost Management and Restructuring - The company completed a $30 million restructuring program, expecting an additional $7.5 million in cost savings in Q4 [13] - A $60 million manufacturing optimization effort is underway to improve margins [13] Outlook - Management revised full-year guidance, projecting sales between $1.825 billion and $1.850 billion, and adjusted EBITDA between $400 million and $410 million [15][16] - The company anticipates a stronger Q4, driven by cost savings from restructuring [15] - Key focus areas include organic volume stabilization, margin control, and inventory management [16][17]

Core Insights - Element Solutions (ESI) reported revenue of $625.2 million for the quarter ended June 2025, marking a year-over-year increase of 2% and a surprise of +3.35% over the Zacks Consensus Estimate of $604.97 million [1] - The earnings per share (EPS) for the same period was $0.37, compared to $0.36 a year ago, resulting in an EPS surprise of +2.78% against the consensus estimate of $0.36 [1] Financial Performance Metrics - Net Sales in the Industrial & Specialty segment were $185.8 million, exceeding the average estimate of $178.67 million by three analysts, but reflecting a year-over-year decline of -15.9% [4] - Net Sales in the Electronics segment reached $439.4 million, surpassing the average estimate of $426.27 million, with a year-over-year increase of +12.2% [4] - Adjusted EBITDA for the Industrial & Specialty segment was $39.5 million, above the average estimate of $34 million [4] - Adjusted EBITDA for the Electronics segment was $96.5 million, slightly below the average estimate of $97.03 million [4] Stock Performance - Shares of Element Solutions have returned +2.6% over the past month, compared to a +3.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Financial Performance - Hawkins' 2025 revenue reached $9744 million[10] - The company's 5-year EPS CAGR is 25%[10] - Net income in fiscal year 2025 was $843 million, with a 24% CAGR[67] - Adjusted EBITDA in fiscal year 2025 was $1675 million, with a 21% CAGR[69] - Diluted EPS in fiscal year 2025 was $403, with a 25% CAGR[74] - Q1 Fiscal Year 2026 revenue reached a record $2933 million, a 15% increase year-over-year[81] - Q1 Fiscal Year 2026 Adjusted EBITDA reached a record $574 million, a 13% increase year-over-year[81] Business Segments - Water Treatment accounted for 46% of revenue, totaling $4465 million[15] - Food & Health Sciences accounted for 33% of revenue, totaling $3225 million[15] - Industrial Solutions accounted for 21% of revenue, totaling $2054 million[15] Capital Allocation - The company has consistently returned capital to shareholders through dividends and share repurchases[32] - Hawkins has a track record of 40 consecutive years of cash dividends[33]

Core Insights - AMG Critical Materials N.V. reported a strong second quarter in 2025, with revenue of $439 million, a 20% increase from $364 million in the same period of 2024 [1] - Adjusted EBITDA reached $71 million, marking a 79% increase compared to $39 million in the second quarter of 2024, driven primarily by the AMG Technologies segment [1][5] Financial Performance - Revenue for Q2 2025 was $439 million, up 20% from $364 million in Q2 2024 [1][9] - Adjusted gross profit was $97 million, a 60% increase from $60 million in Q2 2024 [8][9] - Operating profit surged to $33.6 million, a 225% increase from $10.3 million in the same quarter last year [9] - Net income attributable to shareholders was $11.5 million, compared to a loss of $11 million in Q2 2024 [9] - Adjusted EBITDA margin improved to 16.1% from 10.8% year-over-year [9] Segment Performance - AMG Technologies segment achieved an adjusted EBITDA of $53 million, nearly tripling from $18 million in Q2 2024, driven by a high order backlog and strong profitability from AMG Antimony [5][20] - AMG Lithium's revenue decreased by 3% to $37 million, primarily due to a 38% decline in lithium market prices and a 22% decrease in lithium concentrate volumes [11][14] - AMG Vanadium's revenue fell by 4% to $161 million, attributed to lower volumes of ferrovanadium and titanium alloys, despite increased sales prices [14][15] Operational Developments - The lithium hydroxide refinery in Bitterfeld was successfully commissioned in May 2025, with production ramping up and qualification processes with customers advancing [3] - AMG Vanadium successfully bid for significant quantities of spent catalyst in Saudi Arabia and the Middle East, which will help stabilize supply deliveries [7][18] Liquidity and Financial Health - As of June 30, 2025, AMG had total liquidity of $462 million, including $262 million in unrestricted cash and $200 million available on its revolving credit facility [8][27] - The company recorded a net finance cost of $13 million, up from $8 million in Q2 2024, due to foreign exchange losses and decreased interest income [28] Outlook - The company raised its adjusted EBITDA outlook for 2025 from $170 million to $200 million or more, reflecting strong performance in the first half of the year despite low lithium and vanadium prices [29]

Financial Data and Key Metrics Changes - Q3 sales were $463 million, down 15% year over year, including a $53 million impact from portfolio optimization, with organic sales declining 5% primarily due to lower volumes [14][8] - Adjusted EBITDA was $113 million, down 19% year over year or 10% excluding portfolio actions, with adjusted EBITDA margins at 24.4%, down 120 basis points [15][8] - Adjusted EPS, excluding acquisition amortization, was $1.04, down 30% from the prior year, with a noncash goodwill impairment of $6 million recorded [16][8] Business Line Data and Key Metrics Changes - Life Sciences sales were $162 million, down 17% year over year, primarily due to portfolio optimization initiatives, with organic sales declining just 1% [18][9] - Personal Care sales were $147 million, down 16% year over year, driven by portfolio optimization actions, with organic sales declining 6% [24][9] - Specialty Additives sales declined 13% to $131 million, with organic sales and volumes both down 11% [29][9] Market Data and Key Metrics Changes - Life Sciences maintained strong margins of 33% for the second consecutive quarter despite a mixed demand environment [9][10] - Intermediates faced a challenging supply-demand landscape, particularly in Europe, with sales down to $33 million from $36 million year over year [21][9] - Personal Care showed early signs of recovery, particularly in biofunctional actives, with sales up double digits supported by a robust commercial pipeline [25][9] Company Strategy and Development Direction - The company completed its portfolio optimization and restructuring program ahead of schedule, focusing on cost savings and operational efficiency [12][11] - The strategic imperative is to drive consistent operations at higher utilization rates while balancing cost actions with strategic reinvestment [33][12] - The company aims to expand its reach in underpenetrated markets and drive differentiation through innovation [12][11] Management's Comments on Operating Environment and Future Outlook - Management noted that while the external environment remains uncertain, the company is executing with discipline and focus, positioning for long-term resilient performance [12][11] - The company expects full-year fiscal 2025 sales of approximately $1.825 billion to $1.85 billion and adjusted EBITDA in the range of $400 million to $410 million [45][12] - Management highlighted that demand patterns remain mixed, with pharma steady and personal care showing encouraging signs of recovery [42][12] Other Important Information - The company generated nearly 100% free cash flow conversion in the quarter, demonstrating the strength of its underlying business [15][8] - Liquidity at quarter end was over $800 million, with net leverage at 2.9 times, providing flexibility for strategic investments [17][8] - The company is actively monitoring tariff-related uncertainties but does not anticipate a material direct impact on fiscal year 2025 results [43][12] Q&A Session Summary Question: Insights on fiscal year 2026 outlook and demand recovery - Management indicated that while they are not providing guidance for fiscal year 2026, they see stable demand in personal care and pharma, with potential upside in specialty additives depending on market conditions [50][51] Question: Clarification on cost savings from restructuring and network optimization - Management confirmed that incremental savings in fiscal year 2026 should be in the range of $55 million to $60 million year over year, with restructuring actions completed [74][75] Question: Stability in personal care markets and customer feedback - Management noted stability in mass brands and some variability in the prestige segment, with positive traction observed in Asia and Europe [66][67]

earnings conference call third quarter fiscal 2025 July 30, 2025 O Regulation G: Adjusted Results the information presented herein regarding certain uncudited adjusted results does not conform to generally accepted accounting principles in the United Srates (U.S. GAAP) should not be construed as an affernative to the reported results determined in accordance with U.S. GAAP. Ashland has included this non-GAAP information to assis in understranding the operating performance of the company ond its reportable s ...

Financial Data and Key Metrics Changes - The company reported second quarter adjusted net income of $12 million, up 27% from $9.4 million in the prior year, driven by earnings growth in polymers and crop productivity, as well as a lower tax rate [9][11] - Adjusted EBITDA for the second quarter was $51.4 million, an 8% increase from $47.7 million in the prior year [14] - Cash from operations was $11.2 million for the quarter, while free cash flow was negative at $14.4 million due to inventory builds [12][19] Business Line Data and Key Metrics Changes - Polymers delivered double-digit adjusted EBITDA growth, while surfactant adjusted EBITDA remained similar to last year, impacted by raw material inflation [6][7] - Surfactant net sales were $411.5 million, an 8% increase year-over-year, with selling prices up 11% [15] - Specialty product net sales increased by 22% to $20.5 million, but adjusted EBITDA decreased by 24% due to order timing fluctuations [18] Market Data and Key Metrics Changes - Volume grew 1%, with polymers up 7% and NCT product line up 49%, while surfactants volume was down 1% [8] - North America and European rigid polyols volume grew low single digits, while the commodity PA business showed strong year-over-year growth [8] - The company experienced double-digit volume growth in crop productivity and oilfield end markets, offset by lower demand in global commodity consumer products [8] Company Strategy and Development Direction - The company aims to recover margins gradually and continues to focus on customer acquisition within Tier two and Tier three segments [6][20] - Investments are being made in new product development, particularly in the spray foam end market and next-generation polytechnologies [22] - The company is on track to close the sale of its site in the Philippines in 2025 and is looking for opportunities to optimize its asset base [24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about delivering full-year adjusted EBITDA and net income growth despite market uncertainties [24] - The company is focused on enhancing operational excellence to grow volume and improve product mix [23] - Management noted that the first half of the year was decent, with growth in adjusted EBITDA across surfactants, polymers, and specialty products [32] Other Important Information - The effective tax rate was 19.2% during the first half of the year, lower than the normal range of 24% to 26% due to favorable discrete items [13] - The company paid $8.7 million in dividends during the quarter and has increased dividends for 57 consecutive years [10] Q&A Session Summary Question: Clarification on one-time impacts in the Surfactants business - Management confirmed that the $6 million includes startup costs from Pasadena, the EPA fine, and environmental remediation reserve adjustments [29][31] Question: Details on raw material impacts and pricing - Management indicated that coconut oil prices have significantly increased, and they are still catching up on price execution [34][35] Question: Effects of the new collective bargaining agreement in Millsdale - Management expressed satisfaction with the workforce and noted that the agreement is a routine event occurring every four years [37] Question: Insights on the AOS expansion and its beneficiaries - Management highlighted that AOS is crucial for sulfate-free business growth, targeting both Tier one and lower-tier clients [43] Question: Future asset optimization opportunities - Management stated they are continuously evaluating their asset base for productivity and return on investment, with no concrete plans yet [46] Question: Clarification on the tax benefit seen in the quarter - Management confirmed that the tax benefit was a one-time occurrence and the normal tax rate will return to the range of 24% to 26% [47]

Financial Performance - Value-added (VA) sales reached $269 million, a 2% organic decrease year-over-year[9] - Adjusted EBITDA margin was a record 20.8% of VA, amounting to $55.8 million[9] - Adjusted EPS was $1.37, a 21% sequential increase[9] - Approximately $36 million in free cash flow was generated[9] - The company is on track to deliver 70%+ free cash flow conversion for the full year[9] Segment Performance - Performance Materials' value-added sales were $168.5 million[35] with adjusted EBITDA of $41.5 million, or 24.6% of VA[36] - Electronic Materials' value-added sales were $76.1 million[42] with adjusted EBITDA of $17.8 million, up 4% year-over-year[42], achieving a record adjusted EBITDA margin of 23.4%, up 230 bps year-over-year[20, 44] - Precision Optics' value-added sales were $24.4 million[47] with adjusted EBITDA of $2.2 million, up 5%[47], and adjusted EBITDA margins up 950 bps sequentially[20] Capital Allocation and Outlook - 100,000 shares were repurchased during the quarter at an average of ~$78/share[10, 20] - Full year adjusted EPS guidance of $5.30 - $5.70 is affirmed[20, 54] - Capital expenditures are projected at $70 million for 2025[56]